%20-%20http://www.bohemiancoding.com/sketch%20--%3e%3ctitle%3eIcon/Menu%3c/title%3e%3cdesc%3eCreated%20with%20Sketch.%3c/desc%3e%3cdefs%3e%3cpolygon%20id='path-1'%20points='0.0005%200.646%2022.386%200.646%2022.386%203.1455%200.0005%203.1455'%3e%3c/polygon%3e%3cpolygon%20id='path-3'%20points='0.0005%200.9341%2022.386%200.9341%2022.386%203.4341%200.0005%203.4341'%3e%3c/polygon%3e%3cpolygon%20id='path-5'%20points='0.0005%200.5%2022.386%200.5%2022.386%203%200.0005%203'%3e%3c/polygon%3e%3c/defs%3e%3cg%20id='Symbols'%20stroke='none'%20stroke-width='1'%20fill='none'%20fill-rule='evenodd'%3e%3cg%20id='Icon/Menu'%3e%3cg%20id='Group-10-Copy'%20transform='translate(3.800000,%205.300000)'%3e%3cg%20id='Group-3'%20transform='translate(0.000000,%200.354500)'%3e%3cmask%20id='mask-2'%20fill='white'%3e%3cuse%20xlink:href='%23path-1'%3e%3c/use%3e%3c/mask%3e%3cg%20id='Clip-2'%3e%3c/g%3e%3cpath%20d='M22.3865,2.6455%20C22.3865,2.9205%2022.1615,3.1455%2021.8865,3.1455%20L0.5005,3.1455%20C0.2245,3.1455%200.0005,2.9205%200.0005,2.6455%20L0.0005,1.1455%20C0.0005,0.8705%200.2245,0.6455%200.5005,0.6455%20L21.8865,0.6455%20C22.1615,0.6455%2022.3865,0.8705%2022.3865,1.1455%20L22.3865,2.6455%20Z'%20id='Fill-1'%20fill='%23FFFFFF'%20mask='url(%23mask-2)'%3e%3c/path%3e%3c/g%3e%3cg%20id='Group-6'%20transform='translate(0.000000,%207.354500)'%3e%3cmask%20id='mask-4'%20fill='white'%3e%3cuse%20xlink:href='%23path-3'%3e%3c/use%3e%3c/mask%3e%3cg%20id='Clip-5'%3e%3c/g%3e%3cpath%20d='M22.3865,2.9341%20C22.3865,3.2091%2022.1615,3.4341%2021.8865,3.4341%20L0.5005,3.4341%20C0.2245,3.4341%200.0005,3.2091%200.0005,2.9341%20L0.0005,1.4341%20C0.0005,1.1591%200.2245,0.9341%200.5005,0.9341%20L21.8865,0.9341%20C22.1615,0.9341%2022.3865,1.1591%2022.3865,1.4341%20L22.3865,2.9341%20Z'%20id='Fill-4'%20fill='%23FFFFFF'%20mask='url(%23mask-4)'%3e%3c/path%3e%3c/g%3e%3cg%20id='Group-9'%20transform='translate(0.000000,%2015.354500)'%3e%3cmask%20id='mask-6'%20fill='white'%3e%3cuse%20xlink:href='%23path-5'%3e%3c/use%3e%3c/mask%3e%3cg%20id='Clip-8'%3e%3c/g%3e%3cpath%20d='M22.3865,2.5%20C22.3865,2.775%2022.1615,3%2021.8865,3%20L0.5005,3%20C0.2245,3%200.0005,2.775%200.0005,2.5%20L0.0005,1%20C0.0005,0.725%200.2245,0.5%200.5005,0.5%20L21.8865,0.5%20C22.1615,0.5%2022.3865,0.725%2022.3865,1%20L22.3865,2.5%20Z'%20id='Fill-7'%20fill='%23FFFFFF'%20mask='url(%23mask-6)'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23fff'%20fill-rule='nonzero'%3e%3cg%20id='icon/fold'%20transform='translate(240.000000,%20272.000000)'%3e%3cpath%20d='M11.5,2.3%20C6.4216,2.3%202.3,6.4216%202.3,11.5%20C2.3,16.5784%206.4216,20.7%2011.5,20.7%20C16.5784,20.7%2020.7,16.5784%2020.7,11.5%20C20.7,6.4216%2016.5784,2.3%2011.5,2.3%20Z%20M10.58,18.7956%20C6.946,18.3448%204.14,15.2536%204.14,11.5%20C4.14,10.9296%204.2136,10.3868%204.3332,9.8532%20L8.74,14.26%20L8.74,15.18%20C8.74,16.192%209.568,17.02%2010.58,17.02%20L10.58,18.7956%20Z%20M16.928,16.4588%20C16.6888,15.7136%2016.008,15.18%2015.18,15.18%20L14.26,15.18%20L14.26,12.42%20C14.26,11.914%2013.846,11.5%2013.34,11.5%20L7.82,11.5%20L7.82,9.66%20L9.66,9.66%20C10.166,9.66%2010.58,9.246%2010.58,8.74%20L10.58,6.9%20L12.42,6.9%20C13.432,6.9%2014.26,6.072%2014.26,5.06%20L14.26,4.6828%20C16.9556,5.7776%2018.86,8.418%2018.86,11.5%20C18.86,13.4136%2018.124,15.1524%2016.928,16.4588%20Z'%20id='形状'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
媒體文章
了解權威媒體如何報道藥明康德賦能醫藥健康產業的專題文章、訪談，從第三方視角，展現藥明康德的CRDMO能力與對全球生命科學創新的貢獻。
了解權威媒體如何報道藥明康德賦能醫藥健康產業的專題文章、訪談，從第三方視角，展現藥明康德的CRDMO能力與對全球生命科學創新的貢獻。
筛选
全部年份
2025/09/23
媒體聲音 | 藥明康德一體化CRDMO如何助力北歐創新發展？
近日，藥明康德新藥發現業務副總裁Dave Madge博士接受歐洲行業媒體《北歐生命科學新聞》（Nordic Life Science News）的採訪，他為斯堪的納維亞半島地區的創新活力而感到振奮，也提到，無論是初創企業，還是大型製藥公司，藥明康德的一體化CRDMO平臺都能為他們創造價值，助力當地創新生態圈的發展。
閲讀更多2025/09/01
對話陳民章博士：25年來，藥明康德如何加速新藥誕生？
在藥明康德成立25周年之際，陳民章博士應邀接受知名產業媒體BioWorld專訪，回顧公司的發展歷程，並分享藥明康德獨特的CRDMO業務模式如何為生物醫藥行業的客戶們降低研發門檻，提升研發效率，為全球病患帶來突破性的治療方案。
閲讀更多2025/08/22
25載平臺之路，Co-CEO陳民章博士談藥明康德如何賦能產業創新
日前，行業媒體Pharma Manufacturing的主編Greg Slabodkin採訪了公司聯席首席執行官陳民章博士。陳民章博士擁有二十多年新藥研發和生產管理經驗，在多個全球新藥的研發及商業化過程中發揮了重要作用。
閲讀更多2025/07/24
攻克“不可成藥”：楊青博士談創新療法的突破與合作
近日，藥明康德聯席首席執行官楊青博士與權威行業媒體STAT對談，分享了他對TPD如何改寫癌症和其他疾病治療前景的洞見，並對一體化CRDMO平臺在加速此類藥物研發方面的作用進行了深度解讀。
閲讀更多2025/07/08
藥明康德慕尼黑基地：坐鎮「歐洲醫藥高地」，賦能全球創新夥伴
在今年的歐洲產業大會——BayOConnect年會上，藥明康德德國慕尼黑基地負責人Thomas Meins博士在專題對話中探討了CRDMO模式在創新生態圈中的關鍵作用。在深入剖析慕尼黑生物技術生態系統的同時，他也介紹了像藥明康德這樣的全球合作夥伴如何賦能當地乃至全球客戶，讓這一生態系統更具創新活力。
閲讀更多